Investigational drug · Phase 2
ENTR-601-44
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Duchenne Muscular Dystrophy (DMD).
Phase 2Last checked: Nov 20, 2026Latest source record: Aug 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "ENTR-601-44"
First trial start
2025
Jun 30, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ENTR-601-44", any sponsor or status.
Conditions studied
As listed on its trial records.
- Duchenne Muscular Dystrophy (DMD)
Approved drugs for the same conditions: Duchenne muscular dystrophy · Neurology · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "ENTR-601-44" as an intervention, largest first.
Entrada Therapeutics, Inc.Industry
NCT07682129 · 80 participants (planned) · Start Aug 2026 · Primary completion Mar 2032
Drug: ENTR-601-44; ENTR-601-45 · For: Duchenne Muscular Dystrophy (DMD)
Sites: Ghent, Belgium; Leuven, Belgium; Liège, Belgium · 17 sites in all
Entrada Therapeutics, Inc.Industry
NCT07037862 · 24 participants (planned) · Start Jun 30, 2025 · Primary completion Mar 28, 2029
Drug: ENTR-601-44; ENTR-601-44 - matching placebo · For: Duchenne Muscular Dystrophy (DMD)
Sites: Ghent, Belgium; Leuven, Belgium; Liège, Belgium · 14 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Comprehensive review of adverse reactions and toxicology in ASO-based therapies for Duchenne Muscular Dystrophy: From FDA-approved drugs to peptide-conjugated ASO.
Sabrina Haque U, Kohut M, Yokota T · Curr Res Toxicol 2024
Also in development for Duchenne Muscular Dystrophy (DMD)
- Zeleciment RostudirsenDYNE-251Phase 32 trials
Dyne Therapeutics · Duchenne Muscular Dystrophy (DMD), Muscular Dystrophy, Duchenne, Muscular Dystrophy (DMD)
- BrogidirsenNS-089, NCNP-02Phase 23 trials
NS Pharma, Inc. · Duchenne Muscular Dystrophy, Exon 44, DMD
- BMN 351Phase 22 trials
BioMarin · Duchenne Muscular Dystrophy (DMD), Duchenne Muscular Dystrophy
- ENTR-601-45Phase 22 trials
Entrada Therapeutics, Inc. · Duchenne Muscular Dystrophy (DMD)
- SAT-3247Phase 22 trials
Satellos Bioscience, Inc. · Duchenne Muscular Dystrophy, Duchenne, DMD
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.